{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:32:09Z","timestamp":1794274329073,"version":"4.9.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guizhou High-Level Talent Program","award":["GCC[2022]019"],"award-info":[{"award-number":["GCC[2022]019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-96699-9","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:03:15Z","timestamp":1744815795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Histone methyltransferase SMYD2 regulates the activation of hepatic stellate cells by activating TLR4 signaling"],"prefix":"10.1038","volume":"15","author":[{"given":"Kaize","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"96699_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva, T. & Brenner, D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 18, 151\u2013166 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"96699_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hep.32285","volume":"75","author":"SL Friedman","year":"2022","unstructured":"Friedman, S. L. & Pinzani, M. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology 75, 473\u2013488 (2022).","journal-title":"Hepatology"},{"key":"96699_CR3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3390\/cells10051097","volume":"10","author":"A Khanam","year":"2021","unstructured":"Khanam, A., Saleeb, P. G. & Kottilil, S. Pathophysiology and treatment options for hepatic fibrosis: can it be completely cured. Cells 10, 1097 (2021).","journal-title":"Cells"},{"key":"96699_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich, L. & Tacke, F. Hepatic inflammatory responses in liver fibrosis. Nat. Rev. Gastroenterol. Hepatol. 20, 633\u2013646 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"96699_CR5","doi-asserted-by":"publisher","first-page":"106507","DOI":"10.1016\/j.phrs.2022.106507","volume":"185","author":"S Khanmohammadi","year":"2022","unstructured":"Khanmohammadi, S. & Kuchay, M. S. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease. Pharmacol. Res. 185, 106507 (2022).","journal-title":"Pharmacol. Res."},{"key":"96699_CR6","doi-asserted-by":"publisher","unstructured":"Gao, Y. et al. Scoparone alleviates hepatic fibrosis by inhibiting the TLR-4\/NF-\u03baB pathway. J. Cell. Physiol. https:\/\/doi.org\/10.1002\/jcp.30083","DOI":"10.1002\/jcp.30083"},{"key":"96699_CR7","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.18632\/aging.103002","volume":"12","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4\/NF-\u03baB pathway. Aging (Albany NY). 12, 6058\u20136066 (2020).","journal-title":"Aging (Albany NY)"},{"key":"96699_CR8","doi-asserted-by":"publisher","first-page":"105910","DOI":"10.1016\/j.phrs.2021.105910","volume":"173","author":"T Xue","year":"2021","unstructured":"Xue, T. et al. Epigenetic regulation in fibrosis progress. Pharmacol. Res. 173, 105910 (2021).","journal-title":"Pharmacol. Res."},{"key":"96699_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.7150\/thno.46360","volume":"11","author":"Y Jiang","year":"2021","unstructured":"Jiang, Y. et al. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis. Theranostics 11, 361\u2013378 (2021).","journal-title":"Theranostics"},{"key":"96699_CR10","doi-asserted-by":"publisher","first-page":"100167","DOI":"10.1016\/j.jhepr.2020.100167","volume":"2","author":"MG Fern\u00e1ndez-Barrena","year":"2020","unstructured":"Fern\u00e1ndez-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C. & Avila, M. A. Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg. JHEP Rep. 2, 100167 (2020).","journal-title":"JHEP Rep."},{"key":"96699_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1039\/D1CB00196E","volume":"3","author":"A Feoli","year":"2022","unstructured":"Feoli, A. et al. Lysine methyltransferase inhibitors: where we are now. RSC Chem. Biol. 3, 359\u2013406 (2022).","journal-title":"RSC Chem. Biol."},{"key":"96699_CR12","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1002\/ctm2.591","volume":"11","author":"WJ Wu","year":"2021","unstructured":"Wu, W. J. et al. SMYD2-mediated TRAF2 methylation promotes the NF-\u03baB signaling pathways in inflammatory diseases. Clin. Transl Med. 11, e591 (2021).","journal-title":"Clin. Transl Med."},{"key":"96699_CR13","doi-asserted-by":"publisher","first-page":"109040","DOI":"10.1016\/j.abb.2021.109040","volume":"712","author":"A Rueda-Robles","year":"2021","unstructured":"Rueda-Robles, A., Audano, M. & \u00c1lvarez-Mercado, A. I. Rubio-Tom\u00e1s, T. Functions of SMYD proteins in biological processes: what do we know? An updated review. Arch. Biochem. Biophys. 712, 109040 (2021).","journal-title":"Arch. Biochem. Biophys."},{"key":"96699_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3892\/etm.2021.9611","volume":"21","author":"T Tian","year":"2021","unstructured":"Tian, T. et al. IOX1 protects from TGF-\u03b2 induced fibrosis in LX-2 cells via the regulation of extracellular matrix protein expression. Exp. Ther. Med. 21, 180 (2021).","journal-title":"Exp. Ther. Med."},{"key":"96699_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13148-019-0711-4","volume":"11","author":"X Yi","year":"2019","unstructured":"Yi, X., Jiang, X. J. & Fang, Z. M. Histone methyltransferase SMYD2: ubiquitous regulator of disease. Clin. Epigenetics. 11, 112 (2019).","journal-title":"Clin. Epigenetics"},{"key":"96699_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s00018-023-04883-9","volume":"80","author":"LR Liu","year":"2023","unstructured":"Liu, L. R. et al. SMYD2 regulates vascular smooth muscle cell phenotypic switching and intimal hyperplasia via interaction with myocardin. Cell. Mol. Life Sci. 80, 264 (2023).","journal-title":"Cell. Mol. Life Sci."},{"key":"96699_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/cells12010025","volume":"12","author":"K Xu","year":"2022","unstructured":"Xu, K. et al. SMYD2 promotes hepatocellular carcinoma progression by reprogramming glutamine metabolism via c-Myc\/GLS1 axis. Cells 12, 25 (2022).","journal-title":"Cells"},{"key":"96699_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41419-021-03720-w","volume":"12","author":"L Wu","year":"2021","unstructured":"Wu, L. et al. SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7. Cell. Death Dis. 12, 439 (2021).","journal-title":"Cell. Death Dis."},{"key":"96699_CR19","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00452.2021","volume":"323","author":"LX Li","year":"2022","unstructured":"Li, L. X. et al. Cross talk between lysine methyltransferase Smyd2 and TGF-\u03b2-Smad3 signaling promotes renal fibrosis in autosomal dominant polycystic kidney disease. Am. J. Physiol. Ren. Physiol. 323, F227\u2013F242 (2022).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"96699_CR20","doi-asserted-by":"publisher","first-page":"e21715","DOI":"10.1096\/fj.202000554RRR","volume":"35","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis. FASEB J. 35, e21715 (2021).","journal-title":"FASEB J."},{"key":"96699_CR21","first-page":"588","volume":"41","author":"B Zeng","year":"2021","unstructured":"Zeng, B. et al. [Inhibitory effect of Xinhui citrus fermentation liquor on liver fibrosis in mice]. Nan Fang Yi Ke Da Xue Xue Bao. 41, 588\u2013592 (2021).","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"96699_CR22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/jat.4728","volume":"45","author":"Y Mao","year":"2025","unstructured":"Mao, Y. et al. Ergothioneine ameliorates liver fibrosis by inhibiting glycerophospholipids metabolism and TGF-\u03b2\/Smads signaling pathway: based on metabonomics and network Pharmacology. J. Appl. Toxicol. 45, 514\u2013530 (2025).","journal-title":"J. Appl. Toxicol."},{"key":"96699_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397\u2013411 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"96699_CR24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/gutjnl-2023-329671","volume":"73","author":"M Kong","year":"2024","unstructured":"Kong, M. et al. Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis. Gut 73, 810\u2013824 (2024).","journal-title":"Gut"},{"key":"96699_CR25","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cells8111419","volume":"8","author":"B Dewidar","year":"2019","unstructured":"Dewidar, B., Meyer, C., Dooley, S. & Meindl-Beinker, A. N. TGF-\u03b2 in hepatic stellate cell activation and liver Fibrogenesis-Updated 2019. Cells 8, 1419 (2019).","journal-title":"Cells"},{"key":"96699_CR26","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","volume":"74","author":"Z oyer-Diaz","year":"2021","unstructured":"oyer-Diaz, Z. et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J. Hepatol. 74, 1188\u20131199 (2021).","journal-title":"J. Hepatol."},{"key":"96699_CR27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","volume":"36","author":"P Horn","year":"2024","unstructured":"Horn, P. & Tacke, F. Metabolic reprogramming in liver fibrosis. Cell. Metab. 36, 1439\u20131455 (2024).","journal-title":"Cell. Metab."},{"key":"96699_CR28","doi-asserted-by":"publisher","first-page":"1454980","DOI":"10.3389\/fmed.2024.1454980","volume":"11","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Signaling pathways that activate hepatic stellate cells during liver fibrosis. Front. Med. (Lausanne). 11, 1454980 (2024).","journal-title":"Front. Med. (Lausanne)"},{"key":"96699_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/13880209.2022.2030759","volume":"60","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Ranunculus ternatus thunb extract attenuates renal fibrosis of diabetic nephropathy via inhibiting SMYD2. Pharm. Biol. 60, 300\u2013307 (2022).","journal-title":"Pharm. Biol."},{"key":"96699_CR30","doi-asserted-by":"publisher","first-page":"154626","DOI":"10.1016\/j.phymed.2022.154626","volume":"110","author":"C Chen","year":"2023","unstructured":"Chen, C. et al. Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-\u03b2\/Smad signaling. Phytomedicine 110, 154626 (2023).","journal-title":"Phytomedicine"},{"key":"96699_CR31","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/tox.23458","volume":"37","author":"C Wan","year":"2022","unstructured":"Wan, C. et al. Perfluorooctane sulfonate aggravates CCl4-induced hepatic fibrosis via HMGB1\/TLR4\/Smad signaling. Environ. Toxicol. 37, 983\u2013994 (2022).","journal-title":"Environ. Toxicol."},{"key":"96699_CR32","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1002\/jcb.29520","volume":"121","author":"X Liao","year":"2020","unstructured":"Liao, X. et al. MicroRNA-326 attenuates hepatic stellate cell activation and liver fibrosis by inhibiting TLR4 signaling. J. Cell. Biochem. 121, 3794\u20133803 (2020).","journal-title":"J. Cell. Biochem."},{"key":"96699_CR33","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jcmm.16209","volume":"25","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y., Li, Y., Mu, T., Tong, N. & Cheng, P. Hepatic stellate cells specific liposomes with the Toll-like receptor 4 ShRNA attenuates liver fibrosis. J. Cell. Mol. Med. 25, 1299\u20131313 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"96699_CR34","doi-asserted-by":"publisher","first-page":"e31402","DOI":"10.1002\/jcp.31402","volume":"239","author":"X Hou","year":"2024","unstructured":"Hou, X. et al. H3K36 methyltransferase SMYD2 affects cell proliferation and migration in Hirschsprung\u2019s disease by regulating METTL3. J. Cell. Physiol. 239, e31402 (2024).","journal-title":"J. Cell. Physiol."},{"key":"96699_CR35","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/mc.23536","volume":"62","author":"J Li","year":"2023","unstructured":"Li, J. et al. Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling. Mol. Carcinog. 62, 940\u2013950 (2023).","journal-title":"Mol. Carcinog."},{"key":"96699_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jphs.2023.07.003","volume":"153","author":"M Chen","year":"2023","unstructured":"Chen, M. et al. Pharmacological Inhibition of SMYD2 protects against cisplatin-induced renal fibrosis and inflammation. J. Pharmacol. Sci. 153, 38\u201345 (2023).","journal-title":"J. Pharmacol. Sci."},{"key":"96699_CR37","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3389\/fgene.2019.01291","volume":"10","author":"M Zaghi","year":"2019","unstructured":"Zaghi, M., Broccoli, V. & Sessa, A. H3K36 methylation in neural development and associated diseases. Front. Genet. 10, 1291 (2019).","journal-title":"Front. Genet."},{"key":"96699_CR38","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1002\/ctm2.591","volume":"11","author":"W WWu","year":"2021","unstructured":"WWu, W. et al. SMYD2-mediated TRAF2 methylation promotes the NF-\u03baB signaling pathways in inflammatory diseases. Clin. Transl Med. 11, e591 (2021).","journal-title":"Clin. Transl Med."},{"key":"96699_CR39","doi-asserted-by":"publisher","first-page":"829630","DOI":"10.3389\/fphar.2022.829630","volume":"13","author":"B Cui","year":"2022","unstructured":"Cui, B. et al. Pharmacological Inhibition of SMYD2 protects against cisplatin-induced acute kidney injury in mice. Front. Pharmacol. 13, 829630 (2022).","journal-title":"Front. Pharmacol."},{"key":"96699_CR40","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1172\/JCI90921","volume":"127","author":"LX Li","year":"2017","unstructured":"Li, L. X. et al. Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease. J. Clin. Invest. 127, 2751\u20132764 (2017).","journal-title":"J. Clin. Invest."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96699-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:03:16Z","timestamp":1744815796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96699-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96699"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96699-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was approved by the Laboratory Animal Center of Guizhou Medical University (Guizhou, China; approval number 2402260). The study is reported in accordance with ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"13166"}}